-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On May 12, the official website of CDE showed that Hengrui's Class 1 new drug SHR-1905 injection was approved for clinical use, and its indication is asthma.
At present, Hengrui has 2 monoclonal antibody drugs intended for asthma in the clinical stage, namely SHR-1819 targeting IL-4R and SHR-1703 targeting IL-5.
The fastest progress in the world is the TSLP-targeted monoclonal antibody Tezepelumab that Amgen and AstraZeneca collaborated on.
The curative effect of existing biological drugs is associated with increased eosinophil content, which is observed in 60% of patients with moderate to severe asthma.
TSLP is an epithelial cytokine produced in response to pro-inflammatory stimuli (such as lung allergens, viruses, and other pathogens).
According to the Insight database, AstraZeneca has currently carried out a phase III clinical trial of Tezepelumab for asthma in China.